155 related articles for article (PubMed ID: 31752784)
1. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis.
Friebus-Kardash J; Trendelenburg M; Eisenberger U; Ribi C; Chizzolini C; Huynh-Do U; Lang KS; Wilde B; Kribben A; Witzke O; Dolff S; Hardt C
BMC Nephrol; 2019 Nov; 20(1):430. PubMed ID: 31752784
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients.
Chong BF; Tseng LC; Kim A; Miller RT; Yancey KB; Hosler GA
J Dermatol Sci; 2014 Mar; 73(3):216-24. PubMed ID: 24315762
[TBL] [Abstract][Full Text] [Related]
3. Association of the rs1126616 and rs9138 Variants in the
Rivera-Cameras A; Gallegos-Arreola MP; Morán-Moguel MC; Salazar-Páramo M; Alcaraz-López MF; Echeverría-González G; Topete-Reyes JF; Franco-Chávez SA; Dávalos-Rodríguez IP
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256074
[TBL] [Abstract][Full Text] [Related]
4. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.
Evans LS; Lewis KE; DeMonte D; Bhandari JG; Garrett LB; Kuijper JL; Ardourel D; Wolfson MF; Debrot S; Mudri S; Kleist K; Griffin LL; Hebb L; Sanderson RJ; Wang N; Seaberg M; Chunyk AG; Yang J; Hong Y; Maria Z; Messenheimer DJ; Holland PM; Peng SL; Rixon MW; Dillon SR
Arthritis Rheumatol; 2023 Jul; 75(7):1187-1202. PubMed ID: 36705554
[TBL] [Abstract][Full Text] [Related]
5. Intrarenal production of B-cell survival factors in human lupus nephritis.
Neusser MA; Lindenmeyer MT; Edenhofer I; Gaiser S; Kretzler M; Regele H; Segerer S; Cohen CD
Mod Pathol; 2011 Jan; 24(1):98-107. PubMed ID: 20890272
[TBL] [Abstract][Full Text] [Related]
6. Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria.
Wang S; Spielman A; Ginsberg M; Petri M; Rovin BH; Buyon J; Broder A
Clin J Am Soc Nephrol; 2022 Aug; 17(8):1150-1158. PubMed ID: 35882508
[TBL] [Abstract][Full Text] [Related]
7. Polygenic Risk Score Predicts Earlier-Onset Adult Systemic Lupus Erythematosus and First-Year Renal Diseases in a Taiwanese Cohort.
Chen YJ; Hsiao TH; Lin YC; Jeng WJ; Mao CL; Wei CY; Hsieh YC; Huang CJ; Pan MH; Chen IC; Lin CH; Chen YM; Yang HI
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38637112
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in immunotherapies for lupus nephritis.
Kaneko M; Jackson SW
Pediatr Nephrol; 2023 Apr; 38(4):1001-1012. PubMed ID: 35778517
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis.
Nawata A; Nakayamada S; Hisano S; Miyazaki Y; Miyamoto T; Shiba E; Hisaoka M; Tanaka Y
Lupus Sci Med; 2023 Jul; 10(2):. PubMed ID: 37460249
[TBL] [Abstract][Full Text] [Related]
10. Modeling of clinical phenotypes in systemic lupus erythematosus based on the platelet transcriptome and FCGR2a genotype.
Cornwell MG; Bannoudi HE; Luttrell-Williams E; Engel A; Barrett TJ; Myndzar K; Izmirly P; Belmont HM; Clancy R; Ruggles KV; Buyon JP; Berger JS
J Transl Med; 2023 Apr; 21(1):247. PubMed ID: 37029410
[TBL] [Abstract][Full Text] [Related]
11. Improvement of renal and non-renal SLE outcome measures on sirolimus therapy - A 21-year follow-up study of 73 patients.
Piranavan P; Perl A
Clin Immunol; 2021 Aug; 229():108781. PubMed ID: 34144197
[TBL] [Abstract][Full Text] [Related]
12. Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis.
Li Y; Tang C; Vanarsa K; Thai N; Castillo J; Lea GAB; Lee KH; Kim S; Pedroza C; Wu T; Saxena R; Mok CC; Mohan C
J Autoimmun; 2024 Feb; 143():103165. PubMed ID: 38194790
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus.
Sanchez E; Nadig A; Richardson BC; Freedman BI; Kaufman KM; Kelly JA; Niewold TB; Kamen DL; Gilkeson GS; Ziegler JT; Langefeld CD; Alarcón GS; Edberg JC; Ramsey-Goldman R; Petri M; Brown EE; Kimberly RP; Reveille JD; Vilá LM; Merrill JT; Anaya JM; James JA; Pons-Estel BA; Martin J; Park SY; Bang SY; Bae SC; Moser KL; Vyse TJ; Criswell LA; Gaffney PM; Tsao BP; Jacob CO; Harley JB; Alarcón-Riquelme ME; ; Sawalha AH
Ann Rheum Dis; 2011 Oct; 70(10):1752-7. PubMed ID: 21719445
[TBL] [Abstract][Full Text] [Related]
14. Analysis of risk factors and development of a nomogram prediction model for lupus nephritis in systemic lupus erythematosus patients.
Tang Z; Wang JM; Qin JM; Wen LM
Lupus; 2023 Aug; 32(9):1084-1092. PubMed ID: 37480363
[TBL] [Abstract][Full Text] [Related]
15. Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity.
Rezazadeh M; Jokar MH; Mehrnaz Aghili S; Mirfeizi Z; Mahmoudi M; Morovatdar N; Hashemzadeh K
Arch Rheumatol; 2023 Sep; 38(3):429-440. PubMed ID: 38046245
[TBL] [Abstract][Full Text] [Related]
16. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
[TBL] [Abstract][Full Text] [Related]
17. Telitacicept for autoimmune nephropathy.
Cai J; Gao D; Liu D; Liu Z
Front Immunol; 2023; 14():1169084. PubMed ID: 37342346
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients.
Blazer A; Wang B; Simpson D; Kirchhoff T; Heffron S; Clancy RM; Heguy A; Ray K; Snuderl M; Buyon JP
PLoS One; 2017; 12(8):e0182483. PubMed ID: 28850570
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Clinical Features, Treatment and Outcomes of Lupus Nephritis Between Patients With Late- and Early-Onset Systemic Lupus Erythematosus: A Controlled Study.
Mongkolchaiarunya J; Wongthanee A; Kasitanon N; Louthrenoo W
J Clin Med Res; 2024 Mar; 16(2-3):106-117. PubMed ID: 38550544
[TBL] [Abstract][Full Text] [Related]
20. Clinical research progress of novel biologics for the treatment of lupus nephritis.
Cui W; Tian Y; Huang G; Zhang X; Li F; Liu X
Clin Exp Med; 2023 Dec; 23(8):4153-4162. PubMed ID: 37481481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
